查看購物車
  • English
  • Japanese
基因檢測市場規模、佔有率和成長分析（按檢測類型、技術、疾病類型、最終用戶和地區分類）：產業預測（2026-2033 年）
市場調查報告書
商品編碼
2065363

基因檢測市場規模、佔有率和成長分析（按檢測類型、技術、疾病類型、最終用戶和地區分類）：產業預測（2026-2033 年）

Hereditary Testing Market Size, Share, and Growth Analysis, By Test Type (Predictive Testing, Carrier Testing), By Technology, By Disease Type, By End User, By Region - Industry Forecast 2026-2033
出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2024 年全球基因檢測市場價值為 154 億美元，預計到 2033 年將從 2025 年的 174.3 億美元成長到 468.9 億美元，預測期（2026-2033 年）的複合年成長率為 13.17%。

基因檢測市場正經歷強勁成長，這主要得益於精準醫療的日益普及和遺傳疾病盛行率的上升。人們對遺傳健康風險的認知不斷提高，加上定序技術的進步，正在擴大基因組檢測的覆蓋範圍。基因資訊在疾病預防和個人化醫療中的應用日益廣泛，是推動市場擴張的關鍵因素。定序成本的降低和生物資訊學的進步，正在改善不同情況下基因檢測的可及性。此外，臨床醫生和保險公司也認知到基因檢測在改善患者預後和降低長期醫療成本方面的益處。儘管仍存在一些挑戰，例如檢測成本高昂、對基因資料隱私的擔憂、遺傳諮詢服務有限以及保險報銷障礙等，但級聯檢測、產前篩檢和藥物基因組學等領域正在湧現出巨大的機會。

全球基因檢測市場按檢測類型、技術、疾病類型、最終用戶和地區進行細分。按檢測類型分類，市場分為預測性檢測、基因帶原檢測、產前和新生兒檢測、診斷性檢測、藥物基因組學檢測及其他。依技術分類，市場分為次世代定序(NGS)、基於 PCR 的檢測、微陣列檢測、全EXOME定序、全基因測序及其他。依疾病類型分類，市場分為遺傳性癌症檢測、心血管遺傳疾病、神經系統遺傳疾病、罕見疾病和遺傳性疾病、代謝性疾病及其他。按最終用戶分類，市場分為醫院和診所、診斷檢測實驗室、學術和研究機構、專業基因中心及其他。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球基因檢測市場的成長要素

全球基因檢測市場正受到次世代定序平台普及的顯著推動。這些平台具有更高的靈敏度和處理能力，增強了識別多種基因變異的能力。這項進步拓展了檢測服務的範圍和臨床應用。臨床檢查室和專業檢測機構提供的多基因panel和全EXOME子定序平台進一步促進了轉診和臨床應用。此外，更高的檢測柔軟性和更低的樣本處理複雜度使得檢體能夠無縫整合到常規工作流程中，從而提高了可及性，並結合資訊解決方案的支持，進一步增強了服務交付能力。

全球基因檢測市場的限制因素

全球基因檢測市場面臨許多挑戰，主要源自於報銷政策的不確定性和不同保險計畫涵蓋範圍的差異。這種不一致會阻礙醫療服務提供者和患者在臨床實踐中充分利用基因檢測。有限的覆蓋範圍或繁瑣的論證要求可能會阻礙醫療服務提供者進行檢測，進而為尋求拓展服務的檢測實驗室帶來運作困難。此外，高昂的自付費用也可能使患者望而卻步，減緩市場整體成長。支付方的分散以及預先核准的要求，造成了沉重的行政負擔，阻礙了檢測服務的拓展。

全球基因檢測市場趨勢

全球基因檢測市場正呈現與精準醫療顯著融合的趨勢，促進醫療策略的個人化。這種整合正在推動包括遺傳學家和腫瘤學家在內的醫療服務提供者之間的協作，並促進基因檢測與電子健康記錄的整合。這些進展有助於長期患者照護、為家庭提供高效的連鎖檢測，以及建立標準化的決策工具。隨著基因檢測的日益普及，它將有助於早期發現遺傳疾病，實現更有效的患者分層，並最終加速臨床療效的改善和轉化研究的進展。

目錄

介紹

  • 分析目的
  • 市場定義和範圍

分析方法

  • 分析過程
  • 二級資料和一級資料的方法
  • 估算市場規模的方法

執行摘要

  • 全球市場展望
  • 市場主要亮點
  • 細分市場概覽
  • 競爭環境概述

市場動態與展望

  • 總體經濟指標
  • 促進者和機會
  • 抑制因素和挑戰
  • 供給面趨勢
  • 需求面趨勢
  • 波特五力分析及其影響

關鍵市場觀察

  • 主要成功因素
  • 影響市場的因素
  • 主要投資機會
  • 生態系測繪
  • 市場魅力指數（2025）
  • PESTLE分析
  • 監理情勢

全球基因檢測市場規模：依檢測類型分類

  • 預測性測試
  • 基因帶原檢測
  • 產前和新生兒篩檢
  • 診斷測試
  • 藥理基因體學檢測
  • 其他

全球基因檢測市場規模：依技術分類

  • 次世代定序（NGS）
  • 基於PCR的檢測
  • 微陣列偵測
  • 全EXOME定序
  • 全基因測序
  • 其他

全球基因檢測市場規模：依疾病類型分類

  • 遺傳性癌症檢測
  • 心血管遺傳疾病
  • 神經系統遺傳疾病
  • 罕見疾病和遺傳疾病
  • 代謝性疾病
  • 其他

全球基因檢測市場規模：依最終用戶分類

  • 醫院和診所
  • 診斷檢查室
  • 學術和研究機構
  • 專業遺傳中心
  • 其他

全球基因檢測市場規模：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太國家
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲國家
  • 中東和非洲
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲國家

競爭格局

  • 前五大公司對比
  • 主要公司的市場定位（2025 年）
  • 主要公司採取的策略
  • 近期市場趨勢
  • 主要公司市佔率（2025 年）
  • 主要公司簡介
    • 公司簡介
    • 產品系列分析
    • 按細分市場進行企業市佔率分析
    • 2023-2025年營收年比比較

主要公司簡介

  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.
  • Myriad Genetics, Inc.
  • Invitae Corporation
  • Natera, Inc.
  • Quest Diagnostics Incorporated
  • Laboratory Corporation of America Holdings（Labcorp）
  • Eurofins Scientific SE
  • Exact Sciences Corporation
  • Centogene NV
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • GeneDx Holdings Corp.
  • SOPHiA GENETICS SA
  • Ambry Genetics Corporation
  • NeoGenomics Laboratories, Inc.
  • 3billion, Inc.

結論與建議

簡介目錄
Product Code: SQMIG35D2499

Global Hereditary Testing Market size was valued at USD 15.4 Billion in 2024 and is poised to grow from USD 17.43 Billion in 2025 to USD 46.89 Billion by 2033, growing at a CAGR of 13.17% during the forecast period (2026-2033).

The hereditary testing market is witnessing robust growth, fueled by the rising adoption of precision medicine and the increasing prevalence of inherited disorders. Enhanced awareness of genetic health risks, coupled with advancements in sequencing technologies, has broadened access to genomic testing. A major driver of market expansion is the high utilization of genetic information in disease prevention and personalized healthcare. Cost reductions in sequencing and improvements in bioinformatics are enhancing testing accessibility in various settings. Moreover, clinicians and payers recognize the benefits of hereditary testing for improving patient outcomes and lowering long-term healthcare costs. While challenges such as high testing costs, genetic data privacy concerns, limited genetic counseling access, and reimbursement hurdles exist, significant opportunities arise from cascade testing, prenatal screening, and pharmacogenomics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hereditary Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hereditary Testing Market Segments Analysis

Global hereditary testing market is segmented by test type, technology, disease type, end user, and region. Based on test type, the market is segmented into predictive testing, carrier testing, prenatal & newborn testing, diagnostic testing, pharmacogenomic testing, and others. Based on technology, the market is segmented into Next-Generation Sequencing (NGS), PCR-based testing, microarray testing, whole exome sequencing, whole genome sequencing, and others. Based on disease type, the market is segmented into hereditary cancer testing, cardiovascular genetic disorders, neurological genetic disorders, rare & inherited diseases, metabolic disorders, and others. Based on end user, the market is segmented into hospitals & clinics, diagnostic laboratories, academic & research institutes, specialty genetic centers, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Driver of the Global Hereditary Testing Market

The Global Hereditary Testing market is significantly driven by the widespread adoption of next-generation sequencing platforms, which enhance the ability to identify various hereditary variants with improved sensitivity and throughput. This advancement has broadened the range of testing services and applications in clinical environments. The availability of multigene panels and whole exome platforms through both clinical laboratories and specialized testing providers has further promoted referrals and clinical utilization. Additionally, greater assay flexibility and reduced complexity for individual samples allow for seamless integration into routine workflows, thereby improving accessibility and contributing to expanded service capacity alongside supporting informatics solutions.

Restraints in the Global Hereditary Testing Market

The Global Hereditary Testing market faces significant challenges due to the unpredictability of reimbursement policies and varying levels of coverage among insurance plans. This inconsistency can hinder both providers and patients from fully embracing hereditary testing in clinical practice. When coverage is limited or demands extensive justification, healthcare providers may hesitate to implement testing, leading to operational difficulties for laboratories striving to scale their services. Additionally, patients may shy away from testing due to potential high out-of-pocket expenses, stalling overall market growth. The fragmented payer environment, coupled with demands for prior authorizations, imposes considerable administrative burdens that discourage expansive testing initiatives.

Market Trends of the Global Hereditary Testing Market

The Global Hereditary Testing market is experiencing a significant trend towards the integration of precision medicine, enhancing the personalization of healthcare strategies. This integration is fostering a collaborative environment among healthcare providers, including geneticists and oncologists, and facilitating the incorporation of hereditary testing into electronic health records. Such advancements support long-term patient care, efficient cascade testing for families, and the establishment of standardized decision-making tools. As hereditary testing becomes more widely implemented, it enhances the early identification of inherited disorders and allows for more effective stratification of patients, ultimately improving clinical outcomes and accelerating translational research pathways.

Table of Contents

Introduction

  • Objectives of the Study
  • Market Definition & Scope

Research Methodology

  • Research Process
  • Secondary & Primary Data Methods
  • Market Size Estimation Methods

Executive Summary

  • Global Market Outlook
  • Key Market Highlights
  • Segmental Overview
  • Competition Overview

Market Dynamics & Outlook

  • Macro-Economic Indicators
  • Drivers & Opportunities
  • Restraints & Challenges
  • Supply Side Trends
  • Demand Side Trends
  • Porters Analysis & Impact
    • Competitive Rivalry
    • Threat of Substitute
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factors
  • Market Impacting Factors
  • Top Investment Pockets
  • Ecosystem Mapping
  • Market Attractiveness Index 2025
  • PESTEL Analysis
  • Regulatory Landscape

Global Hereditary Testing Market Size by Test Type & CAGR (2026-2033)

  • Market Overview
  • Predictive Testing
  • Carrier Testing
  • Prenatal & Newborn Testing
  • Diagnostic Testing
  • Pharmacogenomic Testing
  • Others

Global Hereditary Testing Market Size by Technology & CAGR (2026-2033)

  • Market Overview
  • Next-Generation Sequencing (NGS)
  • PCR-Based Testing
  • Microarray Testing
  • Whole Exome Sequencing
  • Whole Genome Sequencing
  • Others

Global Hereditary Testing Market Size by Disease Type & CAGR (2026-2033)

  • Market Overview
  • Hereditary Cancer Testing
  • Cardiovascular Genetic Disorders
  • Neurological Genetic Disorders
  • Rare & Inherited Diseases
  • Metabolic Disorders
  • Others

Global Hereditary Testing Market Size by End User & CAGR (2026-2033)

  • Market Overview
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Specialty Genetic Centers
  • Others

Global Hereditary Testing Market Size & CAGR (2026-2033)

  • North America (Test Type, Technology, Disease Type, End User)
    • US
    • Canada
  • Europe (Test Type, Technology, Disease Type, End User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Test Type, Technology, Disease Type, End User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Test Type, Technology, Disease Type, End User)
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Test Type, Technology, Disease Type, End User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • F. Hoffmann-La Roche Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Illumina, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • QIAGEN N.V.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Thermo Fisher Scientific Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Myriad Genetics, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Invitae Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Natera, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Quest Diagnostics Incorporated
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Laboratory Corporation of America Holdings (Labcorp)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eurofins Scientific SE
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Exact Sciences Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Centogene N.V.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bio-Rad Laboratories, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Agilent Technologies, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BGI Genomics Co., Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GeneDx Holdings Corp.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • SOPHiA GENETICS SA
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ambry Genetics Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • NeoGenomics Laboratories, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • 3billion, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations